Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Novartis looking for new homes for midphase asthma, eye disease and NASH assets after pipeline review
Fierce Biotech
Tue, 07/19/22 - 10:36 am
Novartis
asthma
NASH
Retinitis pigmentosa
Beyond biopsy: how noninvasive NASH tests can move the needle
Clinical Trials Arena
Fri, 07/15/22 - 12:09 pm
liver biopsies
diagnostics
NASH
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Endpoints
Thu, 07/7/22 - 10:28 am
Intercept Pharma
OCA
obeticholic acid
FDA
NASH
Key data catalysts for the industry’s small players
EP Vantage
Fri, 07/1/22 - 09:35 am
Intercept Pharma
Akero
NASH
Kymera
atopic dermatitis
Zealand Pharma
short bowel syndrome
Relmada
Verona
Anavex
Assembly Biosciences
Aldeyra
After phase 2 flop, Novo Nordisk says its NASH work is 'still very much on track'
Fierce Pharma
Wed, 06/29/22 - 05:43 pm
Novo Nordisk
NASH
semaglutide
89bio’s home run fails to excite
EP Vantage
Wed, 06/29/22 - 10:35 am
89Bio
NASH
pegozafermin
hypertriglyceridemia
Pfizer Makes Supportive Investment in Akero's NASH Drug
BioSpace
Thu, 06/16/22 - 10:45 pm
Akero Therapeutics
Pfizer
NASH
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
Yahoo/Zacks.com
Mon, 05/30/22 - 10:25 am
Pfizer
NASH
FDA
fast track
ervogastat/clesacostat
Pfizer's NASH Treatment Lands FDA Fast Track Designation
BioSpace
Thu, 05/26/22 - 10:44 pm
Pfizer
FDA
NASH
ervogastat/clesacostat
fast track
89bio gains a little more confidence in NASH treatment with new hormone data
Fierce Biotech
Sun, 03/27/22 - 03:52 pm
89Bio
NASH
liver disease
pegozafermin
Going...going...gone. A small biotech throws in its IPO cards after market meltdown
Endpoints
Mon, 03/21/22 - 10:22 pm
Sagimet Biosciences
IPOs
NASH
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster
Fierce Biotech
Sat, 02/12/22 - 11:52 pm
Metacrine
layoffs
NASH
Taking on Big Pharma-sized indications, tiny biotech claims early win in fat loss. Will it translate to diabetes, NASH and beyond?
Endpoints
Wed, 02/9/22 - 10:01 am
Rivus Pharmaceuticals
diabetes
NASH
heart failure
A NASH player touts positive PhIII data, but true test still lies ahead
Endpoints
Mon, 01/31/22 - 11:04 am
NASH
clinical trials
Madrigal Pharmaceuticals
resmetirom
NAFLD
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Tue, 01/4/22 - 10:25 am
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom
Biotech startup lines up more cash to steer its NASH drug through stormy seas
Endpoints
Sat, 12/18/21 - 10:58 pm
NorthSea Therapeutics
NASH
funding
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
BioPharma Dive
Fri, 12/10/21 - 12:00 am
Intercept Pharma
NASH
Europe
obeticholic acid
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
Mon, 11/22/21 - 10:19 pm
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Another NASH player retreats from battered field after toxicology study flags potential delay
Endpoints
Mon, 10/25/21 - 10:55 am
Metacrine
NASH
MET642
clinical trials
IBD
After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever
Endpoints
Tue, 09/21/21 - 10:47 am
Genentech
Jecure Therapeutics
NASH
RNA
858 Therapeutics
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »